Placebo to match BI 730357

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyPsoriasis

Phase 1

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

CompletedNCT04147260

Boehringer IngelheimHealthy

Start: 2019-11-06End: 2020-09-09Updated: 2023-07-17

Phase 2

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

TerminatedNCT03835481

Boehringer IngelheimPsoriasis

Start: 2019-03-18End: 2021-07-27Updated: 2022-11-18

Related Papers

Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Journal of Investigative Dermatology2025-01-215 citations